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PLoS Neglected Tropical Diseases has been
open to submissions since February 2007,
and we have been impressed by the
number, quality, and range of the research
articles we have received to date—from
laboratory studies and assessments of new
diagnostic tests to observational epidemi-
ology, clinical trials, and qualitative re-
search. But we have also noted that some
authors have omitted crucial information
about the ethical conduct of their study, or
have been unaware of international guid-
ance on how to report specific types of
research. We would therefore like to
remind authors of our reporting require-
ments (more detailed guidance is available
at http://www.plosntds.org/guidelines.php).
Ethical Approval and Informed
Consent
Patients with neglected tropical diseases
are among the most economically and
socially disadvantaged people on the
planet. So when it comes to conducting
clinical research among this vulnerable
population, investigators must take partic-
ular precautions to protect the welfare of
research participants.
One crucial precaution that all re-
searchers must take is to seek prior
approval for their study from a relevant
institutional review board (IRB), which
must be named in the paper. We reserve
the right to ask authors to send a copy of
the board’s formal approval. During the
study, if the authors deviated from their
protocol—and particularly if the deviation
exposed participants to any additional
risks—we expect the researchers to have
immediately informed the board about the
deviation and we require documentation
of the board’s response.
Some authors have argued that their
study was exempt from IRB approval since
the data were collected as part of the routine
diagnosis or treatment of patients. But
because of the potential risks involved in
recording data about patients for research
purposes, such as breaches of patient con-
fidentiality, an IRB should be asked to assess
these risks ahead of the study. The IRB may
indeed decide that no specific approval is
required, in which case we ask authors to
send a copy of the IRB exemption letter.
We are aware that in some research
settings there may not be a local IRB.
Under these circumstances, authors should
have made every attempt to find an ethics
committee outside the immediate region to
approve the study. In the very rare event
that it was impossible to find such a com-
mittee, we expect authors to have con-
ducted their study according to the princi-
plesexpressedinthe Declaration ofHelsinki
(http://www.wma.net/e/policy/b3.htm)
and to have familiarized themselves with
accepted international norms and stand-
ards, such as those set out by the Interna-
tional Committee of Medical Journal
Editors (ICMJE; http://www.icmje.org/)
and the Committee on Publication Ethics
(http://www.publicationethics.org.uk/).
A second crucial precaution is that
investigators must obtain fully informed,
ideally written, consent from all partici-
pants in their study. We reserve the right
to ask authors to send a copy of the consent
form that the participants signed. If details
about a specific patient are included in
a paper (e.g., a case description or a clinical
photograph), authors must send a copy of
t h ep a t i e n t ’ sw r i t t e ni n f o r m e dc o n s e n tt o
have these clinical details published in PLoS
Neglected Tropical Diseases (using the consent
form at http://www.plosntds.org/guide
lines.php#supporting, available in English,
French, Spanish, and Portuguese).
Oral consent is acceptable provided
three specific conditions are met: (1)
authors must explain in their paper why
written consent was impossible (e.g., their
study was conducted among an illiterate
population); (2) authors must have docu-
mentary proof that every individual gave
consent (e.g., a literate witness, who ideally
was not part of the research team, signed
on behalf of the participant, and/or there
is an audio or video recording of the oral
consent process); and (3) the IRB specifi-
cally approved the oral informed consent
process [1]. A forthcoming policy article in
PLoS Neglected Tropical Diseases explores in
more detail the issue of obtaining mean-
ingful and valid consent from vulnerable
populations [2].
For animal studies, we ask authors to
name the committee that approved the
study and oversaw animal welfare.
Reporting Guidelines
One of the most important advances in
medical research reporting has been the
development of international standards for
reporting specific study types. PLoS has
adopted these standards for all of its
journals. The best known is the CON-
SORT (Consolidated Standards of Re-
porting Trials) statement. Authors should
supply a completed CONSORT checklist
(available from the CONSORT Web site
at http://www.consort-statement.org/)
and ensure that they include a flow dia-
gram to illustrate participant flow through
the trial. In addition, we strongly encour-
age authors to write their paper using
a template that adopts the CONSORT
section headings, and we have prepared
such a template for you to use (available at
http://www.plosone.org/static/tpl_plos_
clinicaltrials.doc).
Authors of all trials (i.e., any study that
prospectively assigns participants to one
or more interventions) should send the
original trial protocol as a supporting
information file to allow editors and
reviewers to assess the study fully. Any
deviation from the trial protocol must be
explained. We fully support the position of
the ICMJE on trial registration [3]. All
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be registered prospectively in a publicly
accessible registry (before patient recruit-
ment has begun), or they will not be
considered for publication. For trials
initiated before July 1, 2005, all trials must
be registered before submission to our
journals. The trial’s registration number
must be provided at the time of sub-
mission. Acceptable registries are listed on
the World Health Organization’s trials
registration Web site (http://www.who.
int/ictrp/network/list_registers/en/index.
html). Further details on trial registration
are available on the ICMJE’s Web site
(http://www.icmje.org/).
There are four other reporting stand-
ards that we ask authors to adopt.
Systematic reviews should follow the
QUOROM (Quality of Reports of Meta-
Analyses) statement [4], and authors
should include the QUOROM flow chart
and checklist. Any study that reports on
a diagnostic test should conform to the
STARD requirements (http://www.con-
sort-statement.org/index.aspx?o=1031).
Studies of observational epidemiology
(cross-sectional, cohort, or case-control)
should follow the STROBE (Strengthen-
ing the Reporting of Observational Stud-
ies in Epidemiology) statement (http://
www.strobe-statement.org/). Finally, re-
ports of microarray experiments should
conform to the MIAME (Minimum In-
formation About a Microarray Experi-
ment) guidelines (http://www.mged.org/
Workgroups/MIAME/miame.html) and
the data from the experiments must be
deposited in a publicly accessible database
such as GEO (http://www.ncbi.nlm.nih.
gov/geo/) or Array Express (http://www.
ebi.ac.uk/arrayexpress/). Indeed, for all
studies submitted to PLoS Neglected Tropical
Diseases, all appropriate datasets, images,
and information should be deposited in
a relevant public database and the acces-
sion numbers should be given in the paper.
PLoS Neglected Tropical Diseases is com-
mitted to publishing research that not only
advances scientific knowledge on these
diseases of poverty, but that is ethically
sound and reported to the very highest
standards. Please help us in our mission by
following our guidance on ethics and
reporting standards.
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